Detalles de la búsqueda
1.
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Blood
; 135(20): 1739-1749, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32160294
2.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood
; 132(4): 393-404, 2018 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29567798
3.
Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 24(5): 973-982, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29307717
4.
Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 24(5): 945-955, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29275139
5.
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 24(4): 726-733, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29197676
6.
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Haematologica
; 103(8): 1298-1307, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773593
7.
Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Cancer
; 123(17): 3346-3355, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28452054
8.
Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Cancer
; 123(11): 2035-2042, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28117898
9.
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Am J Hematol
; 92(11): 1214-1223, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28815757
10.
Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.
Am J Hematol
; 92(1): 42-49, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27712033
11.
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Blood
; 123(9): 1309-18, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24345751
12.
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Biol Blood Marrow Transplant
; 21(3): 552-8, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25528388
13.
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cancer
; 121(10): 1637-44, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25586015
14.
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Br J Haematol
; 171(4): 539-46, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26248505
15.
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Blood
; 119(15): 3403-12, 2012 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22371878
16.
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Blood
; 119(17): 4083-90, 2012 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22408257
17.
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Am J Hematol
; 89(7): 732-42, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24711212
18.
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Biol Blood Marrow Transplant
; 19(9): 1393-5, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23764455
19.
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood
; 118(17): 4567-76, 2011 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21865346
20.
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
Transfusion
; 53(1): 76-84, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22624594